A carregar...

Managing Acquired Resistance to Third-Generation EGFR Tyrosine Kinase Inhibitors Through Co-Targeting MEK/ERK Signaling

Although epidermal growth factor receptor (EGFR)-targeted therapy has improved clinical outcomes of patients with advanced non-small-cell lung cancer (NSCLC) carrying activating EGFR mutations, the development of acquired resistance to EGFR tyrosine kinase inhibitors (EGFR-TKIs), including the promi...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Lung Cancer (Auckl)
Main Authors: Yu, Danlei, Zhao, Wen, Vallega, Karin A, Sun, Shi-Yong
Formato: Artigo
Idioma:Inglês
Publicado em: Dove 2021
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7872905/
https://ncbi.nlm.nih.gov/pubmed/33574724
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/LCTT.S293902
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!